Exane Derivatives Teva Pharmaceutical Industries LTD Transaction History

Exane Derivatives

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$7.38 - $10.4 $405 - $572	-55 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$7.33 - $9.39 $403 - $516	55 New	55 $0
Q4 2021 Jan 28, 2022	SELL	$7.9 - $10.19 $434 - $560	-55 Closed	0 $0
Q2 2021 Jul 28, 2021	SELL	$9.9 - $11.56 $108,692 - $126,917	-10,979 Reduced 99.5%	55 $0
Q1 2021 Apr 30, 2021	SELL	$10.34 - $12.81 $11,673 - $14,462	-1,129 Reduced 9.28%	11,034 $127,000
Q4 2020 Jan 27, 2021	BUY	$8.61 - $11.04 $19,820 - $25,414	2,302 Added 23.34%	12,163 $117,000
Q3 2020 Oct 08, 2020	BUY	$8.57 - $12.69 $84,508 - $125,136	9,861 New	9,861 $88,000
Q3 2020 Oct 06, 2020	SELL	$8.57 - $12.69 $45,035 - $66,685	-5,255 Closed	0 $0
Q2 2020 Jul 10, 2020	SELL	$8.12 - $13.12 $323,232 - $522,267	-39,807 Reduced 88.34%	5,255 $64,000
Q1 2020 Apr 17, 2020	SELL	$6.69 - $13.45 $68,238 - $137,190	-10,200 Reduced 18.46%	45,062 $404,000
Q4 2019 Jan 22, 2020	BUY	$6.53 - $10.72 $14,163 - $23,251	2,169 Added 4.09%	55,262 $541,000
Q2 2019 Jul 12, 2019	BUY	$8.12 - $15.72 $355,509 - $688,253	43,782 Added 470.22%	53,093 $0
Q1 2019 Apr 24, 2019	BUY	$15.58 - $20.01 $145,065 - $186,313	9,311 New	9,311 $0
Q4 2017 Jan 29, 2018	SELL	$11.23 - $19.1 $364,604 - $620,119	-32,467 Closed	0 $0
Q3 2017 Oct 18, 2017	BUY	$15.41 - $32.17 $500,316 - $1.04 Million	32,467	32,467 $0

603

567M

25.2M

5.08M

Ticker TEVA
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,110,560,000
Market Cap $19.8B
Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage form...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.